Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
  • The group usually releases earnings worse than estimated.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
AIMMUNE THERAPEUTICS, INC.3.05%2 268
-
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273
GENMAB A/S55.72%24 142
BEIGENE, LTD.59.36%24 079
ARGENX SE59.89%12 942
MYOKARDIA, INC.208.58%11 993
-
MIRATI THERAPEUTICS, INC.74.97%11 336
HUALAN BIOLOGICAL ENGINEERI..49.79%11 237
SAREPTA THERAPEUTICS, INC.5.18%10 710
NEUROCRINE BIOSCIENCES, INC..-11.51%8 887
ASCENDIS PHARMA A/S16.55%8 661
ULTRAGENYX PHARMACEUTICAL I..180.57%7 927
More Results
Financials (USD)
Sales 2019 - - -
Net income 2019 -248 M - -
Net cash 2019 89,6 M - -
P/E ratio 2019 -8,43x
Yield 2019 -
Capitalization 2 268 M 2 268 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 339
Free-Float 77,8%
Upcoming event on AIMMUNE THERAPEUTICS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential -
Yield -
Consensus -
7 days EPS revision -
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision